Stereotaxis, Inc. Q1 2010 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2010. Stereotaxis, Inc. designs, manufactures, and markets the NIOBE magnetic navigation system and the ODYSSEY Enterprise Solution for interventional cardiology procedures. The company operates primarily in the U.S., Europe, and Asia.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Total Revenue | $10.62 million | $11.13 million |
| Gross Margin | $7.70 million (72.5%) | $7.67 million (68.9%) |
| Operating Loss | $(6.26) million | $(7.13) million |
| Net Loss | $(8.43) million | $(7.53) million |
| Cash and Equivalents | $24.51 million | $18.80 million |
| Working Capital | $4.15 million | $22.88 million |
| Total Debt (Carrying Amount) | $22.66 million | $23.68 million |
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue decreased 5% year-over-year. System sales revenue dropped 24% (from $6.86M to $5.23M) due to fewer NIOBE system installations (4 vs. 5). Conversely, recurring revenue from disposables, service, and accessories increased 26% (from $4.27M to $5.38M), driven by an expanded installed base.
- Margin Improvement: Gross margin percentage improved to 72.5% from 68.9%, primarily due to the higher proportion of high-margin recurring revenue.
- Expense Reduction: Sales and marketing expenses decreased 10% to $6.70 million, largely due to lower share-based compensation resulting from increased forfeitures. General and administrative expenses decreased 4% due to lower bad debt expense.
- Debt Reclassification: Working capital decreased significantly from $22.9 million to $4.1 million. This was principally caused by the reclassification of approximately $11 million of debt from long-term to current maturities.
- Warrant Liability: The company recorded a $1.54 million non-cash expense related to the mark-to-market adjustment of warrants classified as derivative liabilities, contributing to the net loss.
Outlook, Risks, and Management Commentary
- Liquidity: Management expects negative cash flow from operations in 2010. The company holds $24.5 million in cash and has $5.2 million of additional borrowing capacity under its revolving credit facility. Management believes these resources are sufficient to fund operations for the next 12 months but may require additional financing thereafter.
- Biosense Webster Agreement: A significant portion of the company's debt ($12.5 million) relates to an advance from Biosense Webster. This debt is recouped via royalty deductions. The company must make quarterly "Supplemental Payments" starting May 15, 2010, if royalty recoupments fall below $1 million per quarter. An "Accelerating Recoupment Event" (e.g., raising $50M in equity) would trigger immediate repayment.
- Risks: Key risks include the need for future financing, foreign exchange exposure (11% of revenue in foreign currencies), and the potential for an Accelerating Recoupment Event regarding the Biosense Webster debt.
- Subsequent Events: In April 2010, the company amended its agreement with Biosense Webster to extend exclusive distribution rights for non-irrigated catheters until August 1, 2010, to facilitate negotiations for an expanded collaboration.
Investor Verification Checklist
- Verify the sufficiency of the $24.5 million cash balance against projected operating losses and the upcoming quarterly supplemental payment obligations to Biosense Webster.
- Monitor the "Accelerating Recoupment Event" triggers, specifically any plans for equity financing exceeding $50 million, which would accelerate debt repayment.
- Assess the sustainability of the revenue mix shift toward disposables and services as a hedge against the volatility of system sales.
- Review the impact of the warrant liability mark-to-market adjustments on future net loss figures, as these are non-cash but affect reported earnings.
- Confirm the status of negotiations for the expanded collaboration with Biosense Webster following the April 2010 extension.